Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity

International Journal of Obesity volume 42, pages 1900–1911 (2018)Cite this article

Subjects

Abstract

Introduction

In obese individuals, nonalcoholic fatty liver disease (NAFLD) is common but often goes undiagnosed, and therefore untreated. The presence of significant fibrosis is a key determinant of NAFLD progression, and liver steatosis has substantial cardiovascular implications. We aimed to determine the diagnostic accuracy of common noninvasive diagnostic tests for steatosis and fibrosis in the obese.

Methods

We recruited 182 severely and morbidly obese individuals undergoing bariatric surgery (age 44 ± 12 years, body mass index 45.1 ± 8.3 kg/m2). Medical history, blood tests and liver biopsy were taken on the day of surgery. Serum steatosis and fibrosis scores were calculated. In a subgroup of patients, transient elastography with controlled attenuation parameter (TE/CAP) (n = 82) and proton magnetic resonance spectroscopy (1H-MRS) (n = 49) were performed.

Results

1H-MRS had excellent diagnostic accuracy for steatosis, with strong correlation to steatosis (r = 0.647, p < 0.001), good AUROC (0.852, p = 0.001), sensitivity (81.3%) and specificity (87.5%). However, due to low feasibility in this cohort (65.3% success), this was substantially decreased with intention-to-diagnose analysis (sensitivity 50.0%, specificity 60.9%). CAP had good feasibility (80.5%), and performed better in intention-to-diagnose analysis (AUROC 0.688, sensitivity 84.8%, specificity 47.2%). Serum steatosis scores performed poorly, with comparable accuracy to ALT. For significant fibrosis, TE had the best accuracy (AUROC 0.903, p = 0.007), which remained reasonable after intention-to-diagnose analysis (sensitivity 100%, specificity 59.0%). A combination approach using CAP with ALT for steatosis and TE with Forn index for fibrosis yielded reasonable overall accuracy.

Conclusions

1H-MRS and TE/CAP had greatest accuracy for NAFLD-related steatosis and fibrosis. Failure rates in obesity significantly diminished diagnostic ability. Use of a combination of serum and imaging tests improved overall feasibility of assessment and diagnostic accuracy in obese individuals.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.

    Article  CAS  Google Scholar 

  2. Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic fatty liver disease: A pathogenic duo. Endocr Rev. 2013;34:84–129.

    Article  CAS  Google Scholar 

  3. Goodman ZD. The impact of obesity on liver histology. Clin Liver Dis. 2014;18:33–40.

    Article  Google Scholar 

  4. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–54.

    Article  CAS  Google Scholar 

  5. Angulo P, Kleiner DE, Dam-Larsen S, Adams L, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–97.

    Article  Google Scholar 

  6. Byrne C, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62:S47–S64.

    Article  Google Scholar 

  7. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901–10.

    Article  CAS  Google Scholar 

  8. Targher G, Byrne CD. A perspective on metabolic syndrome and nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2015;13:235–8.

    Article  CAS  Google Scholar 

  9. Manchanayake J, Chitturi S, Nolan C, Farrell GC. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26:510–6.

    Article  CAS  Google Scholar 

  10. Anstee Q, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–44.

    Article  CAS  Google Scholar 

  11. Taitano AA, Markow M, Fiana JE, Wheeler DE, Gonzalvo JP, Murr MM. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2014;19:429–36.

    Article  Google Scholar 

  12. Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–88.

    Article  Google Scholar 

  13. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy - AASLD Position Paper. Hepatology. 2009;49:1017–44.

    Article  Google Scholar 

  14. Castera L. Noninvasive evaluation of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:291–303.

    Article  Google Scholar 

  15. Asrani SK. Incorporation of non-invasive measures of liver fibrosis into clinical practice: diagnosis and prognosis. Clin Gastroenterol Hepatol. 2015;13:2190–204.

    Article  Google Scholar 

  16. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. 2014;156:20–44.

    Article  CAS  Google Scholar 

  17. Uppot RN, Shahani DV, Hahn PF, Gervais D, Mueller PR. Impact of obesity on medical imaging and image-guided intervention. Am J Roentgenol. 2007;188:433–40.

    Article  Google Scholar 

  18. Prati D, Taioli E, Zanella A, Torre ED, Butelli S, Vecchio ED, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.

    Article  CAS  Google Scholar 

  19. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84.

    Article  Google Scholar 

  20. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology. 2010;53:810–20.

    Article  Google Scholar 

  21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.

    Article  Google Scholar 

  22. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease: the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254–69.

    Article  CAS  Google Scholar 

  23. Johnson NA, Walton DW, Sachinwalla T, Thompson CH, Smith K, Ruell PA, et al. Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. Hepatology. 2008;47:1513–23.

    Article  CAS  Google Scholar 

  24. Keating SE, Hackett DA, Parker HM, O’Connor HT, Gerofi JA, Sainsbury A, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol. 2015;63:174–82.

    Article  Google Scholar 

  25. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1209–22.

    Article  CAS  Google Scholar 

  26. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: Burden and severity of subclinial cardiovascular disease among those with nonalcoholic fatty liver; Should we care? Atherosclerosis. 2013;230:258–67.

    Article  CAS  Google Scholar 

  27. Hamirani YS, Pandey S, Rivera JJ, Ndumele C, Budoff MJ, Blumenthal RS, et al. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis. 2008;201:1–7.

    Article  CAS  Google Scholar 

  28. Cobble M, Bale B. Carotid intima-media thickness: knowledge and application to everyday practice. Postgrad Med. 2010;122:10–18.

    Article  Google Scholar 

  29. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433–45.

    Article  Google Scholar 

  30. Naveau S, Lamouri K, Pourcher G, Njike-Nakseu M, Ferretti S, Courie R, et al. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes Surg. 2014;24:1693–701.

    Article  Google Scholar 

  31. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208.

    Article  Google Scholar 

  32. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208.

    Article  Google Scholar 

  33. Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by Fibroscan in nonalcoholic fatty liver disease. J Hepatol. 2016;65:570–8.

    Article  Google Scholar 

  34. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Sys Rev. 2010: CD007340.

  35. Bower G, Toma T, Harling L, Jiao LR, Efthimiou E, Darzi A, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25:2280–9.

    Article  Google Scholar 

  36. National Institute of Health and Care Excellence. Non-alcoholic fatty liver disease: assessment and management of non-alcoholic fatty liver disease (NAFLD) in adults, children and young people. In: NICE guideline—methods, evidence and recommendations. National Institute for Health and Care Excellence; London, UK, 2015.

  37. Kemp W, Roberts SK. FibroScan and transient elastography. Aust Fam Physician. 2013;42:468–71.

    PubMed  Google Scholar 

  38. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8:Suppl 4–Suppl 8.

    Article  Google Scholar 

  39. Teixeira AR, Bellodi-Privato M, Carvalheira JB, Pilla VF, Pareja JC, D’Albuquerque LA. The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory. Obes Surg. 2009;19:1678–84.

    Article  Google Scholar 

  40. Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol. 2011;23:499–506.

    Article  Google Scholar 

  41. Francque SMA, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol. 2012;10:1162–8.

    Article  Google Scholar 

  42. Ooi GJ, Burton PR, Doyle L, Wentworth JM, Bhathal PS, Sikaris K, et al. Effects of bariatric surgery on liver function tests in patients with nonalcoholic fatty liver disease. Obes Surg. 2016;27:1533.

    Article  Google Scholar 

Download references

Author contributions:

All listed authors have contributed to and agree upon the content of the final manuscript. All authors contributed to study conception, design and data acquisition. GO, PB, NJ and AE performed the data analyses. GO, PB and WB drafted the initial version of the manuscript. All authors critically revised and redrafted the manuscript, and all authors approve the final version.

Author information

Authors and Affiliations

  1. Centre for Obesity Research and Education, Central Clinical School, Monash University, Melbourne, Australia

    Geraldine J. Ooi, Paul R. Burton, Cheryl Laurie & Wendy A. Brown

  2. Department of General Surgery, The Alfred Hospital, Melbourne, Australia

    Geraldine J. Ooi, Paul R. Burton & Wendy A. Brown

  3. Department of Epidemiology and Preventative Medicine, School of Public Health and Preventative Medicine, Monash University, Clayton, VIC, Australia

    Arul Earnest

  4. Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia

    William W. Kemp, Ammar Majeed & Stuart K. Roberts

  5. Faculty of Health Science, The University of Sydney, Sydney, Australia

    Nathan Johnson

  6. Department of Pathology, The Alfred Hospital, Melbourne, Australia

    Catriona McLean

Authors
  1. Geraldine J. Ooi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arul Earnest
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William W. Kemp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul R. Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cheryl Laurie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ammar Majeed
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nathan Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Catriona McLean
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Stuart K. Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wendy A. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geraldine J. Ooi.

Ethics declarations

Conflict of interest

GO, PB, CL and WB report being affiliated with the Centre for Obesity Research and Education. The Centre has received funding for research purposes from Allergan and Apollo Endosurgery, the manufacturers of the LapBand™. The grant is not tied to any specific research project, and neither Allergan nor Apollo Endosurgery have control of the protocol, analysis and reporting of any studies. The Centre also receives a grant from Applied Medical towards educational programs. WB reports financial support for a bariatric surgery registry from the Commonwealth of Australia, Apollo Endosurgery, Covidien, Johnson and Johnson, Gore and Applied Medical; and a speaker’s honorarium from Merck Sharpe and Dohme. These are outside of the submitted work. NJ reports speaker’s honorarium from Merck Sharpe & Dohme, which is outside of the submitted work. GO reports scholarships from the National Health and Medical Research Council and the Royal Australasian College of Surgeons. WK, AE, AM, CM, SR have no other disclosures or conflicts of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ooi, G.J., Earnest, A., Kemp, W.W. et al. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. Int J Obes 42, 1900–1911 (2018). https://doi.org/10.1038/s41366-018-0007-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41366-018-0007-3

This article is cited by

Search

Advanced search

Quick links